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Abstract
High-throughput CRISPR screens have shown great promise in functional genomics. We present MAGeCK-VISPR, a
comprehensive quality control (QC), analysis, and visualization workflow for CRISPR screens. MAGeCK-VISPR defines a
set of QC measures to assess the quality of an experiment, and includes a maximum-likelihood algorithm to call
essential genes simultaneously under multiple conditions. The algorithm uses a generalized linear model to
deconvolute different effects, and employs expectation-maximization to iteratively estimate sgRNA knockout
efficiency and gene essentiality. MAGeCK-VISPR also includes VISPR, a framework for the interactive visualization and
exploration of QC and analysis results. MAGeCK-VISPR is freely available at http://bitbucket.org/liulab/mageck-vispr.
Keywords: CRISPR/Cas9, Screening, Maximum likelihood, Expectation-Maximization, Negative binomial, Data-driven
documents, D3, Visualization, Quality control
Background
The clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 system is a powerful genetic
engineering technique, allowing direct modifications of
genomic loci in most model organisms in a cost-effective
way. Based on this system, the recent development of
high-throughput CRISPR screening technology has
shown great promise in functional genomics, allowing
researchers to systematically identify genes associated
with various phenotypes [1–4]. CRISPR screens can be
performed by either direct knockout of genes using
CRISPR/Cas9 [1, 2], or perturbing gene expressions
using CRISPR and a dead-Cas9 (dCas9) fused with acti-
vation or repression effectors [5, 6].
While CRISPR screening is a powerful technique, it
creates computational challenges that include: (1) how
to evaluate the data quality; (2) how to identify gene or
pathway hits from the screens and assess their statistical
significance; and (3) how to visualize and explore the
screening results efficiently. Until now, a comprehensive
quality control (QC), data analysis, and visualization
method for CRISPR screen was not available. Several algo-
rithms are developed for screening analysis on microarray
or high-throughput sequencing data, such as RIGER [7],
RSA [8], HitSelect [9], as well as the MAGeCK algorithm
we previously developed [10]. These algorithms are de-
signed based on a comparison of two conditions, although
many screens are conducted simultaneously across several
time points, under many treatment conditions or over
many cell lines. In addition, these algorithms do not con-
sider the knockout efficiency of single guide RNAs
(sgRNA) on target genes. The knockout efficiency is the
ability of a sgRNA to induce cutting events that lead to
the knockout of the targeted gene. It is influenced by
sgRNA sequence content [11], chromatin accessibility and
exon position of the targeting gene [12], and so on.
In this study, we present MAGeCK-VISPR to over-
come the computational challenges of CRISPR screens.
MAGeCK-VISPR (1) defines a set of QC measurements
and (2) extends the MAGeCK algorithm by a maximum
likelihood estimation method (MAGeCK-MLE) to call
essential genes under multiple conditions while consider-
ing sgRNA knockout efficiency. Further, MAGeCK-VISPR
(3) provides a web-based visualization framework (VISPR)
for interactive exploration of CRISPR screen quality
control and analysis results. MAGeCK-VISPR employs a
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Snakemake [13] workflow to combine MAGeCK and
VISPR in a scalable and reproducible way (Fig. 1).
Results and discussion
Quality control measurements for CRISPR screening
experiments
Apart from the determination of essential genes with
MAGeCK, a central purpose of MAGeCK-VISPR is to
collect quality control (QC) measurements at various
levels (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc). The proposed measurements (Table 1) can be di-
vided into four categories: sequence level, read count level,
sample level, and gene level (Fig. 2).
Sequence level QC measurements aim to detect prob-
lems with the sequencing, similar as in other next-
generation sequencing (NGS) experiments. Two mea-
surements are reported: sample GC content distribution
(Fig. 2a) and the base quality distribution of sequencing
reads (Fig. 2b, c). Ideally, sequencing reads should have
reasonable base qualities (median value >25), and sam-
ples from the same experiment should have similar GC
content distributions.
The second level of QC measurements is based on the
sgRNA read counts collected from MAGeCK. Raw se-
quencing reads are first mapped to sgRNA sequences in
the library with no mismatches tolerated. After that, the
number of sequencing reads, mapped reads (and thereof
the percentage of mapped reads), sgRNAs with zero read
count, and the Gini index of read count distribution are
reported for each sample (Fig. 2d-f ). The percentage of
mapped reads is a good indicator of sample quality, and
low mappability could be due to sequencing error, oligo-
nucleotide synthesis error, or sample contamination.
Good statistical power of downstream analysis relies on
sufficient reads (preferably over 300 reads) for each
sgRNA, with low number of zero-count sgRNAs in the
plasmid library or early time points. Gini index, a com-
mon measure of income inequality in economics, can
measure the evenness of sgRNA read counts [14]. It is
perfectly normal for later time points in positive selection
experiments to have higher Gini index since a few surviv-
ing clones (a few sgRNA with extreme high counts) could
dominate the final pool while most of the other cells die
(more sgRNAs with zero-count). In contrast, high Gini
index in plasmid library, in early time points, or in nega-
tive selection experiments may indicate CRISPR oligo-
nucleotide synthesis unevenness, low viral transfection
efficiency, and over selection, respectively.
Sample level QC (Fig. 2g-j) checks the consistency be-
tween samples. MAGeCK-VISPR reports the distributions
of normalized read counts by box plots and cumulative
distribution functions. It also calculates pairwise Pearson
correlations of sample log read counts, and draws the
samples on the first three components of a Principle
Component Analysis (PCA). Biological replicates or sam-




















Fig. 1 An overview of the MAGeCK-VISPR workflow. Given FASTQ files and an sgRNA design, the workflow employs several preprocessing
steps, including using FastQC and MAGeCK to collect quality control metrics and calculate per-sgRNA read counts. Then, either MAGeCK-RRA
or MAGeCK-MLE is used to determine essential genes under user-defined conditions. Finally, results are composed for visualization and
interactive exploration in VISPR
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count distributions and higher correlations, and appear
closer to each other in the PCA plot. PCA plots can also
identify potential batch effects if the screens are con-
ducted under different batches.
Finally, gene level QC determines the extent of negative
selection in the screens. Since knocking out ribosomal
genes lead to a strong negative selection phenotype [1, 2],
the significance of negative selection on ribosomal genes
can be evaluated in MAGeCK-VISPR by Gene Ontology
(GO) enrichment analysis using GOrilla [15]. A working
negative selection experiment should have a significant P
value (<0.001), although many good experiments could
have much smaller P values (<1e-10, see Section A of
Additional file 1).
Calling essential genes under multiple conditions with
MAGeCK-MLE
MAGeCK-VISPR includes a new algorithm, ‘MAGeCK-
MLE’, to estimate the essentiality of genes in various
screening conditions using a maximum likelihood esti-
mation (MLE) approach. Compared with the original
MAGeCK algorithm using Robust Rank Aggregation
(‘MAGeCK-RRA’) that can only compare samples be-
tween two conditions, MAGeCK-MLE is able to model
complex experimental designs. Furthermore, MAGeCK-
MLE explicitly models the sgRNA knockout efficiency,
which may vary depending on different sequence contents
and chromatin structures [11, 12]. In MAGeCK-MLE, the
read count of a sgRNA i targeting gene g in sample j is
modeled as a Negative Binomial (NB) random variable.
The mean of the NB distribution (μij) is dependent on
three factors: the sequencing depth of sample j (sj), the
knockout efficiency of sgRNA i, and a linear combination
of the effects in different conditions (that is, different drug
treatments) on gene g. If sgRNA i knocks out target gene g
efficiently, then μij is modeled as:





The effects of r different conditions are represented as
the score ‘βgr’, a measurement of gene selections similar
to the term of ‘log fold change’ in differential expression
analysis. The presence or absence of each condition on
each sample is encoded into binary elements of the
design matrix djr, and can be obtained from experiment
designs. ‘β’ scores reflect the extent of selection in each
condition: βgr >0 (or <0) means g is positively (or nega-
tively) selected in condition r. μij is also dependent on
βi0, the initial sgRNA abundance which is usually mea-
sured in plasmid or the day 0 of the experiment.
The values of β, together with the information whether
an sgRNA is efficient, can be estimated by maximizing
the joint log-likelihood of observing all sgRNA read
counts of g on all different samples, and are optimized
using an Expectation-Maximization (EM) algorithm. In
the EM algorithm, MAGeCK-MLE iteratively determines
the knockout efficiency of each sgRNA based on the
current estimation of ‘β’ scores (the E step), and uses the
updated knockout efficiency information to re-calculate
‘β’ scores (the M step). By examining the patterns of read
counts of each sgRNA across all samples, the EM algo-
rithm minimizes the effect of inefficient sgRNAs. A de-
tailed description of the method is presented in the
Methods section.
We tested MAGeCK algorithms on four public data-
sets. The first two datasets (the ‘ESC’ and ‘leukemia’
dataset) correspond to negative selection experiments
on mouse embryonic stem cells (ESCs) and two human
Table 1 Quality control (QC) measures from MAGeCK-VISPR
QC term Description Expected
GC content GC content distribution of the sequencing reads Similar distribution for all samples from same library
Base quality Base quality distribution of the sequencing reads Single-peak distribution with median base quality at least 25
Sequencing reads Total number of sequencing reads Varies depending on sequencing platform
Mapped reads Total number of reads mapped to the sgRNA
library
300 * (number of sgRNAs)
% Mapped reads Percentage of mapped reads to the total number
of sequencing reads
At least 65 %
Zero sgRNAs Number of sgRNAs with zero read counts At most 1 % of total sgRNAs
Gini index Gini index of log-scaled read count distributions At most 0.1 for plasmid or initial state samples, and at most 0.2 for
negative selection samples
Sample correlation Pearson correlation coefficient between samples At least 0.8 for replicates
Correlation clustering or
PCA clustering
Hierarchical clustering of samples or first three
PCA components
Samples with similar conditions should cluster together
Ribosomal gene selection Negative selection enrichment statistics of
ribosomal genes
Significant P values (<0.001) for ribosomal subunit (GO:0044391) in
negative selection experiments
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leukemia cell lines (KBM7 and HL-60), respectively
(Fig. 3a and b) [1, 4]. In both datasets, cells were grown
with their natural growing condition and negative selec-
tions occurred in cells after CRISPR/Cas9 is activated.
The other two datasets (‘melanoma’ knockout and activa-
tion dataset) are different CRISPR screens on the human
melanoma cell line A375 that harbors a BRAF V600E mu-






























































































































Fig. 2 The quality control (QC) view of VISPR, the visualization framework of MAGeCK-VISPR. The measurements include the distribution of GC
content (a), median base quality (b), the distribution of mean sequence quality (c), the number of zero-count sgRNAs (d), Gini-index (e), total
number of reads and the percentage of mapped reads (f), Principle Component Analysis (PCA) plot (g), normalized read count distribution (h, i),
and pairwise sample correlations (j). Shown results are from ESC (a-f) and melanoma dataset (g-j)
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Fig. 3 The gene essentiality scores (β scores) reported from MAGeCK-MLE on two conditions. a, b the β scores of two leukemia cell lines in
the leukemia dataset (a), and two biological replicates of mouse ESC cells in the ESC dataset (b). In (a), some well-known driver genes and cell
type-specific genes are also labeled. These genes may play distinct roles in two different leukemia subtypes (HL60: acute myeloid leukemia;
KBM7: chronic myeloid leukemia), including CDK6 and TRIB1 for HL60, and RUNX1 in KBM7. CDK6 is required in AML growth [17] and TRIB1
over-expression is observed in AML patients compared with CML patients [18]. On the other hand, the frequent RUNX1 loss-of-function
mutations are observed in CML to AML transformations [19]. c An illustration of differentially selected genes identified by two-condition
comparison algorithms (like RRA, blue rectangles). MAGeCK-MLE can further distinguish cell type-specific genes (red dots) from other genes.






























































































































Fig. 4 The β scores of MAGeCK-MLE on the melanoma knockout dataset. a A k-means clustering view of β scores of all conditions from top
selected genes (k = 4). Only genes with the highest or lowest 1 % β scores in DMSO or PLX 14-day treatment conditions are shown. b The
distribution of scores across four conditions using different algorithms. The red rectangle in MAGeCK-MLE indicates genes in cluster 4 in Fig. 4a,
or genes that are strongly positively selected in PLX 14-day condition. Some validated genes in the original study are marked as red dots,
including NF1, NF2, MED12, and CUL3
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inhibitor vemurafenib (PLX) or dimethyl sulfoxide (DMSO)
control, and screened either with GeCKO [2] or with
CRISPR/dCas9 Synergistic Activation Mediator (SAM) li-
braries [5]. These two datasets include multiple experimen-
tal conditions that are difficult to compare directly using
the original MAGeCK-RRA algorithm. In the melanoma
knockout dataset, cells were under 7-day or 14-day selec-
tion [2]. In the melanoma activation dataset, two different
drugs (puromycin and zeocin) were used to select cells with
lentiviral infection, and both DMSO and PLX treatments
were profiled under 3-day or 21-day selection [5].
In two-condition comparisons, MAGeCK-MLE gives
similar results with existing methods such as MAGeCK-
RRA, RSA, and RIGER. All the algorithms identified genes
that are commonly essential to different cell types [16], as
well as known positively selected genes in PLX treated
conditions in two melanoma datasets (Fig. 3; also see Sec-
tion A and B of Additional file 1). In the leukemia dataset,
two-condition comparison algorithms (like MAGeCK-
RRA) identified genes that are differentially selected in
two cell lines by a direct comparison of HL60 and KBM7
(Fig. 3a) [10]. However, not all of these genes are equally
biologically interesting, as MAGeCK-MLE further distin-
guished them into two groups: genes having little effect in
one (β scores close to zero) but strong selection effect in
the other cell line (large absolute β scores), and genes hav-
ing weak and opposite effects in two cell lines (Fig. 3c).
The first group of genes are often more biologically
interesting as they are cell type-specific genes. This in-
cludes some well-known driver genes (like BCR in
KBM7) as well as genes that may be functional in only
one cell type: CDK6 and TRIB1 in HL60 [17, 18], and
RUNX1 in KBM7 [19].
One of the advantages of MAGeCK-MLE over other
methods is that it enables accurate comparisons of gene
essentialities across multiple conditions and experiments
in one run (Fig. 4 and Section C of Additional file 1). In
the melanoma knockout dataset, a k-means clustering of
the β scores of top selected genes demonstrated that these
genes have various essentialities across conditions (Fig. 4a).
Some of the genes are universally positively or negatively
selected in all conditions (cluster 3), while others have dif-
ferent essentiality across different conditions (clusters 1, 2,
and 4). Genes in cluster 4 are particularly interesting as
they show strong positive selection in 14-day PLX treated
condition. Indeed, genes whose knockout leads to strong
positive selection in PLX-treated cells are in cluster 4, in-
cluding NF1, NF2, MED12, CUL3 [2]. In contrast, the k-
means clusters of measurements from other algorithms
did not reveal the strong effect of genes in cluster 4
(Section C of Additional file 1). This is because their
score distributions are similar across different condi-
tions (Fig. 4b), and do not reflect the fact that the one
condition (PLX 14-day treatment) induces much stron-
ger positive selection than other conditions [2]. This is
partly because MAGeCK-RRA, RIGER, and RSA all use
a rank-based method to compare sgRNA between two
conditions, which may lose quantitative information.
Another example of using MAGeCK-MLE on multiple
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Fig. 5 The β scores of MAGeCK-MLE on the melanoma activation dataset. a A k-means clustering view of β scores of all conditions from top selected
genes (k = 5). Only genes with the highest or lowest 1 % β scores in DMSO or PLX 21-day treatment conditions are shown. b the average β scores of
genes in cluster 5 of A (consistently positive selected genes in both zeocin and puromycin conditions), as well as the β scores of these genes
in melanoma knockout dataset. Similar to (a), the k-means clustering algorithm is applied to the selected genes (k = 4)
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dataset, where cells underwent different selection methods
(using puromycin or zeocin), drug treatments (DMSO or
PLX), and durations (3-day or 21-day treatment) (Fig. 5).
Similar to the melanoma knockout dataset, we performed
k-means clustering of the top-selected gene β scores.
Many positively selected genes are dependent on the se-
lection method, which might not be biologically interest-
ing. For example, genes in clusters 2 and 4 correspond to
positively selected genes that are specific to puromycin or
zeocin selection, respectively. A small set of genes (cluster
5) are consistently selected in both zeocin and puromycin,
including genes that are validated in the original study, for
example, EGFR, GPR35, LPAR1/5 [5]. We further exam-
ined the genes in cluster 5 (Fig. 5b), and focused on genes
positively selected in the CRISPR activation experiment
but strongly negatively selected in the knockout experi-
ment. These genes include EGFR and BRAF, two known
kinases that drive melanoma progression and PLX re-
sistance [20, 21], and CRKL, a protein kinase that acti-
vates RAS and JUN pathway. CRKL amplification is
reported to lead to drug resistance against EGFR inhibi-
tors by activating EGFR downstream pathways [22], im-
plying its potential role in PLX drug resistance.
Visualization of QC measurements and gene essentiality
with VISPR
VISPR (VISualization of crisPR screens) is a web-based
frontend for interactive visualization of CRISPR screen QC
and comparison results. Interactive access is provided by an
HTML5 based browser interface, while visualizations are
realized with Vega [23], a declarative visualization grammar
on top of Data-Driven Documents (D3) [24]. VISPR pro-
vides three types of views for interactive exploration of
CRISPR screening: a quality control view, a result view, and
an experiment comparison view. The quality control view
shows the QC measurements described before (Fig. 2).
In the result view, screening results can be inter-
actively explored. It contains a table showing the com-
parison results of each gene (Fig. 6a). The table can be
sorted by different columns and filtered (from ‘Search’)
via gene names or regular expressions. Further, the dis-
tribution of P values is displayed as cumulative distribu-
tion function (CDF) (Fig. 6b) and as a histogram
(Fig. 6c). For each gene, the normalized sgRNA counts
in all samples can be displayed in a parallel coordinate
visualization (Fig. 6d). If available, knockout efficiency
predictions [11] and gene coordinates of each sgRNA
are displayed as separate axes. Axes can be reordered or
toggled on or off, and sgRNAs can be highlighted by
selecting ranges on each axis. Genes selected in the table
are highlighted in the CDF, allowing to assess their oc-
currence within the P value distribution of all genes.
VISPR provides various ways to further explore the ana-
lysis results. Individual genes can be viewed in Ensembl
[25] and IGV [26]. Selected genes can be visualized in
terms of their interaction network and function via Gene-
MANIA [27]. Functional analysis can be performed with
GOrilla [15], an online Gene Ontology (GO) enrichment
analysis tool. GOrilla takes a ranked list of genes (here
based on the P values reported by MAGeCK) to perform
a threshold-free enrichment analysis. The resulting GO
term enrichments can be further used for gene-level qual-
ity control.
The comparison view of VISPR can compare different
experiments by visualizing the common and exclusive sig-
nificant genes via Euler diagrams (Fig. 6e). Clicking on
segments of the Euler diagram opens the result views of
the corresponding experiments. For example, clicking on
the intersection between two experiments will open ‘re-
stricted’ result views for each experiment, where only the
common significant genes are displayed. These views pro-
vide the same features as the unconstrained result views
described above. However, in this case, GO enrichment
analysis with GOrilla is performed with the shown genes
(that is, the genes from the intersection) as foreground
and the other genes of the experiment as background.
The visualizations displayed in VISPR can be down-
loaded as publication-ready SVG files. In addition, a com-
mand line interface is provided to store visualizations as
Vega specifications. This format allows users to modify
and style the output of VISPR programmatically.
Implementation of the MAGeCK-VISPR workflow with
Snakemake
We implemented the MAGeCK-VISPR workflow with the
workflow management system Snakemake [13], allowing
an automatic execution of some or all of the MAGeCK-
VISPR functions: quality control, essential gene analysis,
and visualization. Choosing a workflow management sys-
tem like Snakemake has several advantages. First, the
workflow steps can be automatically parallelized and exe-
cuted on workstations, servers, and compute clusters
without the modification of the workflow. Second, Snake-
make tracks metadata (like creation date, input, and log
files) for all generated result and intermediate files. This
way, used data, methods, and parameters are documented
comprehensively for each analysis (also called data prov-
enance), an important requirement of reproducible sci-
ence. MAGeCK-VISPR provides a command line
interface to initialize the workflow in a given work dir-
ectory. This installs the workflow definition as a so-
called Snakefile, along with a configuration file and docu-
mentation. The configuration file is used to define loca-
tions of raw data and additional parameters for
MAGeCK-VISPR. Once configured, the Snakefile can
be executed with Snakemake. Since the Snakefile is in-
stalled into the given work directory, it can be easily
modified or extended by the user.
Li et al. Genome Biology  (2015) 16:281 Page 7 of 13
We provide all components of the workflow as Conda
packages [28], such that MAGeCK-VISPR can be installed
with a single command. Optionally, the Conda package
manager can create isolated environments for the work-
flow to, for example, freeze or compare different software
versions or publish snapshots of a MAGeCK-VISPR work-
flow instance along with all data and used software. This
further increases the reproducibility of the generated
results.
Conclusion
The recently developed CRISPR screening is a powerful
technology in functional studies with different foci, includ-
ing tumor progression and metastasis [29], drug resistance
[3], immune response [30], and stem cell differentiation
[4]. To our knowledge, MAGeCK-VISPR is the first com-
prehensive pipeline developed for quality control, analysis,
and visualization of CRISPR screens, and highlights new
features compared with existing screening analysis algo-
rithms. For example, a typical CRISPR screening experi-
ment usually includes complex designs that are difficult to
analyze using existing algorithms, as they are all de-
signed for two-condition comparisons. To address this
challenge, MAGeCK-VISPR uses a maximum likelihood
approach to estimate the effect of different conditions
using a generalized linear model (GLM). It also incor-
porates sgRNA knockout efficiency information by
using a probabilistic mixture model. We demonstrated
that MAGeCK-MLE provides additional insights into










































































Fig. 6 The result and comparison views of VISPR. The result view includes a gene comparison table (a), the distribution of P values as CDF (b)
and histogram (c), and the normalized sgRNA counts in all samples of selected genes along with chromosome positions and predicted efficiency
(d). The comparison view of VISPR (e) displays the overlap between significant genes under different selectable conditions and experiments as an
Euler diagram. Shown results are from ESC (a, d) and melanoma dataset (b, c, e)
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gene essentiality scores across conditions or even experi-
ments. Also, MAGeCK-VISPR is able to handle screens of
different types including CRISPR knockout and CRISPR
activation screens, and can be potentially applied to high-
throughput sequencing datasets of traditional RNA inter-
ference (RNAi) screens.
The MAGeCK-MLE approach is able to estimate
sgRNA knockout efficiencies from CRISPR screens be-
sides gene essentiality. We previously reported that
sequence-specific features learned from CRISPR screening
data helped the design of efficient sgRNAs [11]. With
more CRISPR screen data becoming available, the algo-
rithm will help us identify sgRNAs with the best behavior
and learn patterns of ‘good’ sgRNAs. The information will
further guide the design of optimized sgRNAs for CRISPR
screens and individual gene knockouts.
One potential limitation of MAGeCK-MLE is that its
EM algorithm uses an iterative process involving matrix
operations, making it slower than our previous MAGeCK
RRA method and other competing algorithms. Future ap-
proaches to speed up MAGeCK-MLE include improving
parametric tests for P value estimation (instead of using
permutation) and implementing the algorithm in Cython
instead of Python. Another potential limitation of
MAGeCK-VISPR on the quality control assessment is that
the current QC thresholds for ‘successful’ experiments are
determined heuristically due to limited number of publicly
available CRISPR screening datasets. We and other re-
searchers have previously reported that bigger collections
of ChIP-seq datasets provide better criteria on ChIP-seq
quality control [31, 32]. As more public CRISPR screening
datasets become available, the QC metrics (and other parts
of MAGeCK-VISPR) can be further refined.
As CRISPR screens become more popular, complica-
tions in the data such as batch effects will be unavoid-
able which need proper correction for meaningful
downstream analysis. Existing batch removal algo-
rithms, including ComBat [33] and RUVseq [34], have
been widely used to remove batch effects in gene ex-
pression analysis. In the future, these algorithms can
be integrated into MAGeCK-VISPR pipeline. After
that, MAGeCK-VISPR will be able to identify cancer-
and disease-specific essential genes by a direct com-
parison between different datasets or experiments,
providing potentially new therapeutic insights into the
mechanisms of diseases and cancers.
Methods
MAGeCK-MLE: a maximum likelihood approach for
essential gene detection
The Negative Binomial model for high-throughput CRISPR
screening read counts
After read mapping, the sequencing results of CRISPR
screening are presented as a read count table, where
rows correspond to sgRNAs and columns correspond to
samples. Read counts generated from high-throughput
sequencing data have higher variances when a high
number of read counts are observed (also called ‘over-
dispersion’). This is usually modeled using Negative Bi-
nomial (NB) distribution, such as in the statistical
models used in many RNA-seq differential expression
analysis algorithms: edgeR, DESeq/DESeq2, and so on
[35–37]. MAGeCK-MLE uses a similar model; briefly,
the read count of sgRNA i in sample j, or xij, is mod-
eled as:
xij ∼NB μij; αi
 
Where μij and αi are the mean and over-dispersion fac-
tor of the NB distribution, respectively. The mean value
μij is further modeled as:
μij ¼ sjqij ð1Þ
Where sj is the size factor of sample j for adjusting
sequencing depths of the samples, and qij is a vari-
able modeling the behavior of sgRNA i in sample j
that will be discussed in later sections. sj is calcu-
lated by the ‘median ratio method’ in MAGeCK and
DESeq2 [10, 37]:
sj ¼ mediani xijx̂i⋅
 
Here, x^ i is the geometric mean of the read counts of







can also be calculated based on a set of predefined ‘con-
trol’ sgRNAs instead of all sgRNAs. This is particularly
useful when a majority of the genes in the library are
supposed to be essential; in such cases it is not suitable
to calculate sj based on all sgRNAs. Both methods are
implemented in MAGeCK-VISPR and users can specify
which method to use.
The over-dispersion factor αi is calculated based on
the regression residual and will be discussed in more de-
tails in the last Methods section.
Modeling sgRNA knockout efficiency and complex
experimental settings
Different studies demonstrated that sgRNAs have vari-
ous DNA cutting efficiencies [11, 38], but such informa-
tion is not considered in most essential gene calling
algorithms (including MAGeCK). In MAGeCK-MLE, we
use a binary variable πi to model whether sgRNA i is ef-
ficient or not: πi = 1 corresponds to an efficient sgRNA i
and vice versa. Since πi is unknown, the probability of
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observing a read count x from xij is a mixture of two
distributions:
P xij ¼ x
 	 ¼ p xij ¼ xjπi ¼ 1 	p πi ¼ 1ð Þ
þ p xij ¼ xjπi ¼ 0
 	
p πi ¼ 0ð Þ
In CRISPR screening experiments, it is common to
have cells treated with different conditions. For example
in melanoma activation dataset [5], cell lines underwent
different sgRNA expression selection methods (cells are
first selected using puromycin or zeocin), duration of
treatment (3-day or 21-day treatment) and drug treat-
ments (DMSO or PLX). For an efficient sgRNA i (πi = 1),
MAGeCK-MLE uses a generalized linear model (GLM) to
model the effect of qij as a linear combination of effects
from different sources:
P xij ¼ xjπi ¼ 1
 	









Here, βi0 is the baseline abundance of sgRNA i, corre-
sponding to its abundance in an initial state (in plasmid
or day 0). djr is an element of a design matrix given by
the user (explained later), and βgr is the (unknown) coef-
ficient that we would like to estimate.
If sgRNA i is inefficient (πi = 0), then its read counts in
all samples are not determined by any experimental con-
ditions except the baseline abundance:
P xij ¼ xjπi ¼ 0
 	





Design matrices have been used in many gene expression
analysis algorithms for modeling complex experimental de-
signs, including LIMMA [39], VOOM [40], DESeq2 [37],
and so on. The design matrix D models the combination of
effects of different conditions. For J samples that are af-
fected by R conditions, D is a J * R binary matrix with elem-
ent djr = 1 if sample j is affected by condition R, and 0
otherwise. An example of the design matrix is presented in
Additional file 1.
Based on the design matrix, the equations in (2) and
(3) can be written in a matrix form. For a gene g with N
sgRNAs in J samples, let q
→
g be the vector of q values of
all sgRNAs in all samples in gene g:
q
→
g ¼ q11; q21; …; qN1;…; q1J ; q2J ;…; qNJ
 	T






g is a N + r vector of β values in Equations (2)
and (3). The first N elements of β
→
g are the baseline
abundances of N sgRNAs, and the following R elements
of β
→




g ¼ β00; β10;…; βN0; β1;…; βr
 	T
:
The binary extended design matrix D’ is used to set up




g, and can be de-
rived directly from the design matrix. See Additional file
1 for the definition and an example of D’.
The EM approach
MAGeCK-MLE uses a maximum likelihood estimation
(MLE) approach to find the values of β
→
g The objective
























that follows a normal distribution centered
on zero in the objective function. Adding this prior
makes sure β
→
g does not become arbitrarily large, when
the sgRNA knockout efficiency is low and the differ-
ences of read counts between samples are high.
The objective function can be maximized using ex-
pectation maximization (EM). At the beginning, we have
an initial guess of p(πi = 1). Subsequently, we iteratively
update the values of p(πi = 1) and β
→
in the E step and
the M step, respectively.
The initial guess of sgRNA knockout efficiency
We demonstrated that the SSC (Spacer Scoring of
CRISPR) algorithm accurately predicts sgRNA knockout
efficiency from genomic sequence content [11]. For each
sgRNA, SSC generates an efficiency score in the range
(−2,2). We scale the score linearly to the range (0,1) as an
initial guess of p(πi = 1). If no initial estimates are given,
MAGeCK-MLE starts with p(πi = 1) = 1 for all sgRNAs.
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The expectation step
In the E step, we re-estimate the posterior probability
p(πi = 1) and the current estimation of β
→
g :







p xij πi ¼ 1; β→g


 	p πi ¼ 1ð jβ→g Y
j
p xijjπi ¼ 1; β→g
 	







p xij πi ¼ 0; β→g


 	p πi ¼ 0ð jβ→g 
The maximization step
In the M step, we maximize the values of β
→
g based on
the values of p(πi = 1). To derive the formula for updat-
ing β
→
g , we write the probability of observing a read
count x of xij as:
P xij ¼ x
 	 ¼ P xij ¼ xjπi ¼ 1 	I πi¼1ð Þ
 P xij ¼ xjπi ¼ 0
 	I πi¼0ð Þ
where I(.) is an indicator function. Taking the logarithm
on both sides of the equation, we get
logP xij ¼ x
 	 ¼ I πi ¼ 1ð Þ logP xij ¼ xjπi ¼ 1 	
þ I πi ¼ 0ð Þ logP xij ¼ xjπi ¼ 0
 	
In the EM algorithm, it can be approximated by re-
placing the indicator function I(πi = 1) and I(πi = 0) with
the posterior probability of P(πi = 1) and P(πi = 0), re-
spectively [41], using the results from the E step. There-
fore, the log likelihood function from the mixture model
can be written as:
X
i;j









logP xij ¼ xj πi ¼ 1
 	




logP xij ¼ xjπi ¼ 0
 	
Since NB distribution belongs to exponential family
distributions, a fast algorithm exists for the maximum
likelihood estimation of generalized linear models
[42]. Taking the prior of β
→
g into consideration, the ob-
jective function can be maximized using iteratively
reweighted ridge regression, or weighted updates, the
same the algorithm used in DESeq2 [37]. The update
rule for calculating βt
→




¼ ðD0TWD0 þ λIÞ−1D0TW zt
→
Here, W is the diagonal matrix with its values given
by wii = ei
t/(1/μi + αi), where ei
t is the current estimate






xij; βt−1g →Þ ,
λ is the regularization parameter in the ridge regres-
sion, and μi is the current estimate of the mean of
the NB variable:
μt→ ¼ sjexpð ht→Þ
ht−1
→ ¼ D0 βt−1g
→ ð4Þ
z
→t is the residue vector of the current estimate, with
its ith element:
zti ¼ ht−1i þ eti xi−μti
 	
=μti
Here, xi is the read count of sgRNA i.
Convergence
The EM approach iterates the E step and the M step
until it converges or reaches a predefined maximum
number of iteration.
Statistical significance
The statistical significance of β
→
g is calculated in both
permutation and Wald test. In permutation test,
MAGeCK-MLE shuffles all sgRNAs in a gene to gener-
ate empirical null distribution of β
→
g . The number of
shufflings is a parameter specified by the user, and the
default value is set to be 2*(total number of genes). In











































are the diagonal elements of
the covariance matrix of β
→
g.
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Calculating the over-dispersion factor
The over-dispersion factor, αi, is calculated based on the
mean and variance estimation algorithm used in
MAGeCK [10] and VOOM [40]. We first calculate the
fitted values of β
→
g , or β^ g , using the EM algorithm pro-
posed before, with the over-dispersion factor set to a
fixed value (for example, 0.01). Then the fitted means μ^ i
are calculated using Equation (4), and the residual vari-
ances are calculated using the following equation:
σ^ i
2 ¼ xi−μ^ ið Þ2
MAGeCK-MLE then models the sample residual vari-
ance σ^ 2 and fitted mean μ^ using the same model as in
MAGeCK [10]:
σ^ 2 ¼ μ^ þ kμ^b
Where k and b are learned from the fitted means and
residual variances of all sgRNA read counts. The values
of αi are then calculated based on the fitted values of
sample residual variance σ^ f
2 from this model:
αi ¼




The MAGeCK-VISPR workflow is available open source
at http://bitbucket.org/liulab/mageck-vispr under the MIT
license.
Additional file
Additional file 1: Supplementary materials. (PDF 2045 kb)
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